Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome von Hughes, Maria Celia, Wright, Annaliesa, Barbour, Andrew, Thomas, Janine, Smithers, B. Mark, Green, Adele C., Khosrotehrani, Kiarash

Volltext

A More Permanent Crash Pad von Barbour, Celia

Volltext

A Place to Get Better, and Thrive von Barbour, Celia

Volltext

Revealing a Magical Life With Light and a Lens von Barbour, Celia

Volltext

In a house, you can make all the noise you want von Barbour, Celia

Volltext

Coming Up for Air von Barbour, Celia

Volltext

The Ultimate Recyclers von Barbour, Celia

Volltext

The Guilt of Having a Good Thing von Barbour, Celia

Volltext

An Author Discovers, And Then Writes, 'The Best Place to Be' von Barbour, Celia

Volltext

When privacy is not quite the point von Barbour, Celia

Volltext

At a Modernist Landmark, The New Guard Moves In von Barbour, Celia

Volltext

Finding a Co-op Where Owners Cooperate von Barbour, Celia

Volltext

Leaving Home, But Paying Homage To Its History von Barbour, Celia

Volltext

Nourishing Creativity With Order and Care von Barbour, Celia

Volltext

Prospective study of patterns of surgical management in adults with primary cutaneous melanoma at high risk of spread, in Queensland, Australia von Smithers, B. Mark, Hughes, Maria Celia B, Beesley, Vanessa L, Barbour, Andrew P, Malt, Maryrose K, Weedon, David, Zonta, Mark J, Wood, Dominic, Triscott, Joseph A, Bayley, Gerard J, Brown, Lee J, Allan, Christopher P, D'Arcy, Justin, Williamson, Richard, Khosrotehrani, Kiarash, Green, Adele

Volltext bestellen

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy von Lafayette, Richard, Barbour, Sean, Israni, Rubeen, Wei, Xuelian, Eren, Necmi, Floege, Jürgen, Jha, Vivekanand, Kim, Sung Gyun, Maes, Bart, Phoon, Richard K.S., Singh, Harmeet, Tesař, Vladimír, Lin, Celia J.F., Barratt, Jonathan

Volltext

812 Phase 2b ORIGIN study open label extension with atacicept in patients with IgA nephropathy and persistent proteinuria: week 72 interim analysis von Lafayette, Richard, Maes, Bart, Israni, Rubeen, Lin, Celia, Wei, Xuelian, Barbour, Sean, Phoon, Richard, Kim, Sung Gyun, Tesar, Vladimir, Floege, Jürgen, Jha, Vivekanand, Barratt, Jonathan

Volltext

123 Impact of atacicept on hematuria in IGA nephropathy: post-hoc analysis of the phase 2b ORIGIN study von Floege, Jürgen, Barratt, Jonathan, Maes, Bart, Cooper, Kerry, Lin, Celia, Wei, Xuelian, Barbour, Sean, Phoon, Richard, Kim, Sung Gyun, Tesar, Vladimir, Jha, Vivekanand, Wadhwani, Shikha, Lafayette, Richard

Volltext

Atacicept 150 mg Reduces Serum Gd-IgA1, a Biomarker Associated with Long-Term Outcomes in IgA Nephropathy (IgAN): 36W Results from the Ph2b ORIGIN Study: SA-PO887 von Barratt, Jonathan, Maes, Bart D., Lin, Celia J., Wei, Xuelian, Barbour, Sean, Phoon, Richard K., Kim, Sung Gyun, Tesar, Vladimir, Floege, Jürgen, Jha, Vivekanand, Lafayette, Richard A.

Volltext

Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia von Beesley, Vanessa L., Smithers, B. Mark, Khosrotehrani, Kiarash, Khatun, Mohsina, O'Rourke, Peter, Hughes, Maria Celia B., Malt, Maryrose K., Zonta, Mark J., Bayley, Gerard J., Barbour, Andrew P., Brown, Lee J., D'Arcy, Justin, Allan, Christopher P., Green, Adèle C.

Volltext